We are monitoring the impact of COVID-19 on MEA Ophthalmic Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5307
Share on
Share on

Middle East and Africa Ophthalmic Drugs Market Research Report - Segmented By Therapeutic Class, Product Type, Distribution Channel, Disease Indication, Dosage Form, Technology and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 5307
Pages: 145

MEA Ophthalmic Drugs Market Size (2021 to 2026)

The size of the Middle East and Africa ophthalmic drugs market is estimated to be worth USD 2.96 billion by 2026 and USD 2.71 billion in 2021, growing at a CAGR of 1.80% during the forecast period. It captures 8% of the global market.

The rise in the prevalence of eye diseases such as glaucoma, cataract, macular degeneration, and the spike in demand for ophthalmic medications and increased investment in R&D activities by various healthcare businesses are a few factors promoting the growth of the ophthalmic drugs market in the MEA region. Because intraocular lenses are implanted in humans when the natural lens is surgically removed due to cataracts, and phacoemulsification devices are required to perform cataract surgeries, an increase in the incidence of ocular and ophthalmic conditions is driving demand for intraocular lenses and phacoemulsification devices. The rise in middle-class families, advancements in medical infrastructure, and rising health insurance coverage in the Middle East and Africa are expected to impact this growth substantially. In addition, the ophthalmic medication industry is bolstered by the introduction of new effective ophthalmic drugs. In addition, pollution of the air and water put the eyes in more danger. As a result, demand for the medications increases, driving the Middle East and Africa ophthalmic drug market forward.

The market is further expected to be favored by the increase in demand for ophthalmic medications, increased awareness about healthcare to avoid the risk of eye diseases, and government initiatives to develop and manufacture various combinations of ophthalmic drugs. Additionally, increased awareness of the prevention and treatment of eye disease and increased demand for sophisticated healthcare facilities and significant companies operating in the area are driving the market forward. Furthermore, over the forecast period, the growing prevalence of eye-related diseases such as diabetic retinopathy, macular degeneration, and presbyopia is likely to drive market expansion. Furthermore, ophthalmic pharmaceutical firms are pursuing strategic collaborations, acquisitions, and partnerships to extend their product pipeline with new clinical-stage opportunities, which is a positive trend.

During the forecast period, the market growth is likely to be restricted by the length of time required to manufacture and formulate ophthalmic medications and the adverse effects of ophthalmic drugs. In addition, the ophthalmology business has a significant challenge due to a lack of health insurance among the public, particularly in this region, or a lack of insurance in nations that cover all types of IOLs or contact lenses.

This research report on the Middle East and Africa ophthalmic drugs market has been segmented and sub-segmented into the following categories:

By Therapeutic Class: 

  • Anti-inflammatory Drugs
  • Anti-infective Drugs
  • Anti-glaucoma Drugs
  • Anti-allergy Drugs
  • Anti-VEGF Agents
  • Others

By Product Type: 

  • Prescription Drugs
  • Over-the-Counter Drugs 

By Distribution Channel: 

  • Hospital Pharmacies
  • Online Pharmacies
  • Independent Pharmacies
  • Drug Stores 

By Disease Indications: 

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation
  • Retinal Disorders
  • Allergy
  • Uveitis
  • Others  

By Dosage Form: 

  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Other Ophthalmic Drug Forms       

By Technology: 

  • Biologics
  • Cell Therapy
  • Gene Therapy
  • Drug Delivery
  • Small molecule
  • Others 

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, it is expected to grow robustly in the forecast period. The ophthalmological drugs market in the Middle East and Africa is primarily supported by the private sector initiatives in the United Arab Emirates and high healthcare spending in undeveloped African nations such as Rwanda, Uganda, and Malawi. The government of the United Arab Emirates has taken steps to improve ophthalmological medical care in the nation, including the creation of eye specialty hospitals throughout the country's major and semi-urban regions. The need for ophthalmic medicines is growing as the frequency of eye disorders rises. Diabetic retinopathy has been put on the priority list since diabetes has increased in many areas. Hereditary ophthalmic diseases, neurovascular retinal abnormalities, and retinoblastoma benefit from gene therapy for diagnosis and treatment. As a result, further research is needed to optimize and broaden gene therapy's applicability across ophthalmic diseases.

KEY MARKET PLAYERS:

Companies leading the MEA ophthalmic drugs market profiled in the report are Carl-Zeiss AG, Ellex Medical Lasers Ltd., Hoya Corporation, Novagali Pharma S A, Abbott Medical Optics, Inc., Essilor International S.A. Other players in the market include Insight Vision Inc., Nidek Co.Ltd, Topcon Corporation, and Ziemer Ophthalmic Systems AG.

1. Introduction            

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods     

                1.4 General Study Assumptions                

2. Research Methodology 

                2.1 Introduction          

                2.2 Research Phases 

           2.2.1 Secondary Research           

           2.2.2 Primary Research 

           2.2.3 Econometric Modelling      

           2.2.4 Expert Validation  

                2.3 Analysis Design    

                2.4 Study Timeline     

3. Overview                  

                3.1 Executive Summary                

                3.2 Key Inferences    

                3.3 Epidemology         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)               

                4.1 Market Drivers     

                4.2 Market Restraints                    

                4.3 Key Challenges    

                4.4 Current Opportunities in the Market         

5. Market Segmentation    

                5.1 Therapeutic Class

           5.1.1 Introduction           

           5.1.2 Anti-inflammatory Drugs  

      5.1.2.1 Nonsteroidal Anti-inflammatory Drugs

      5.1.2.2 Steroids

           5.1.3 Anti-infective Drugs            

      5.1.3.1 Anti-fungal Drugs

      5.1.3.2 Anti-bacterial Drugs

      5.1.3.3 Others

           5.1.4 Anti-glaucoma Drugs          

      5.1.4.1 Alpha Agonist

      5.1.4.2 Beta Blockers

      5.1.4.3 Prostaglandin Analogs

      5.1.4.4 Combined Medication

      5.1.4.5 Others

           5.1.5 Anti-allergy Drugs

           5.1.6 Anti-VEGF Agents

           5.1.7 Others      

           5.1.8 Y-o-Y Growth Analysis, By Therapeutic Class            

           5.1.9 Market Attractiveness Analysis, By Therapeutic Class          

           5.1.10 Market Share Analysis, By Therapeutic Class         

                5.2 Product Type        

           5.2.1 Introduction           

           5.2.2 Prescription Drugs               

           5.2.3 Over-the-Counter Drugs   

           5.2.4 Y-o-Y Growth Analysis, By Product Type    

           5.2.5 Market Attractiveness Analysis, By Product Type  

           5.2.6 Market Share Analysis, By Product Type    

                5.3 Distribution Channel          

           5.3.1 Introduction           

           5.3.2 Hospital Pharmacies            

           5.3.3 Online  Pharmacies              

           5.3.4 Independent Pharmacies & Drug Stores    

           5.3.5 Y-o-Y Growth Analysis, By Distribution Channel      

           5.3.6 Market Attractiveness Analysis, By Distribution Channel    

           5.3.7  Market Share Analysis, By Distribution Channel     

                5.4 Disease Indications                 

           5.4.1 Introduction           

           5.4.2 Dry Eye     

           5.4.3 Glaucoma

           5.4.4 Infection/Inflammation     

           5.4.5 Retinal Disorders  

      5.4.5.1 Wet Age-related Macular Degeneration

      5.4.5.2 Dry Age-related Macular Degeneration

      5.4.5.3 Diabetic Retinopathy

      5.4.5.4 Others

           5.4.6 Allergy      

           5.4.7 Uveitis      

           5.4.8 Others      

           5.4.9 Y-o-Y Growth Analysis, By Disease Indications         

           5.4.10 Market Attractiveness Analysis, By Disease Indications    

           5.4.11 Market Share Analysis, By Disease Indications      

                5.5 Dosage Form        

           5.5.1 Introduction           

           5.5.2 Liquid Ophthalmic Drug Forms        

           5.5.3 Solid Ophthalmic Drug Forms          

           5.5.4 Semisolid Ophthalmic Drug Forms

           5.5.5 Multicompartment Drug Delivery Systems               

           5.5.6 Other Ophthalmic Drug Forms        

           5.5.7 Y-o-Y Growth Analysis, By Dosage Form     

           5.5.8  Market Attractiveness Analysis, By Dosage Form  

           5.5.9  Market Share Analysis, By Dosage Form   

                5.6 Technology                 

           5.6.1 Introduction           

           5.6.2 Biologics   

           5.6.3 Cell Therapy           

           5.6.4 Gene Therapy       

           5.6.5 Drug Delivery         

           5.6.6 Small molecule      

           5.6.7 Others      

           5.6.8 Y-o-Y Growth Analysis, By Technology        

           5.6.9 Market Attractiveness Analysis, By Technology      

           5.6.10 Market Share Analysis, By Technology     

6. Geographical Analysis    

                6.1 Introduction          

           6.1.1 Regional Trends    

           6.1.2 Impact Analysis     

           6.1.3 Y-o-Y Growth Analysis        

      6.1.3.1 By Geographical Area

      6.1.3.2 By Therapeutic Class

      6.1.3.3 By Product Type

      6.1.3.4 By Distribution Channel

      6.1.3.5 By Disease Indication

      6.1.3.6 By Dosage Form

      6.1.3.7 By Technology

           6.1.4  Market Attractiveness Analysis     

      6.1.4.1 By Geographical Area

      6.1.4.2 By Therapeutic Class

      6.1.4.3 By Product Type

      6.1.4.4 By Distribution Channel

      6.1.4.5 By Disease Indication

      6.1.4.6 By Dosage Form

      6.1.4.7 By Technology

           6.1.5  Market Share Analysis      

      6.1.5.1 By Geographical Area

      6.1.5.2 By Therapeutic Class

      6.1.5.3 By Product Type

      6.1.5.4 By Distribution Channel

      6.1.5.5 By Disease Indication

      6.1.5.6 By Dosage Form

      6.1.5.7 By Technology

                6.2 Middle-East           

                6.3 Africa       

7. Strategic Analysis                  

                7.1 PESTLE analysis    

           7.1.1 Political     

           7.1.2 Economic 

           7.1.3 Social         

           7.1.4 Technological         

           7.1.5 Legal          

           7.1.6 Environmental       

                7.2 Porter’s Five analysis         

           7.2.1 Bargaining Power of Suppliers        

           7.2.2 Bargaining Power of Consumers    

           7.2.3 Threat of New Entrants     

           7.2.4 Threat of Substitute Products and Services              

           7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                   

                8.1 Abbott Medical Optics, Inc.                 

           8.1.1 Overview 

           8.1.2 Product Analysis   

           8.1.3 Financial analysis  

           8.1.4 Recent Developments       

           8.1.5 SWOT analysis       

           8.1.6 Analyst View          

                8.2 Carl-Zeiss AG        

                8.3 Ellex Medical Lasers Ltd.  

                8.4 Essilor International S.A.  

                8.5 Hoya Corporation                    

                8.6 Insight Vision Inc.                     

                8.7 Nidek Co.Ltd         

                8.8 Novagali Pharma S A          

                8.9 Topcon Corporation           

                8.10 Ziemer Ophthalmic Systems AG.                    

9. Competitive Landscape 

                9.1 Market share analysis       

                9.2 Merger and Acquisition Analysis  

                9.3 Agreements, collaborations and Joint Ventures    

                9.4 New Product Launches    

10. Market Outlook and Investment Opportunities                    

Appendix 

                a) List of Tables                

                b) List of Figures         

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms product type and Packaged Containers along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East and Africa Ophthalmic Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  2. Middle East and Africa Dry Eye Market, By Region, From 2021 to 2026 (USD Billion)
  3. Middle East and Africa Glaucoma Market, By Region, From 2021 to 2026 (USD Billion)
  4. Middle East and Africa Infection/Inflammation Market, By Region, From 2021 to 2026 (USD Billion)
  5. Middle East and Africa Retinal Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  6. Middle East and Africa Allergy Market, By Region, From 2021 to 2026 (USD Billion)
  7. Middle East and Africa Uveitis Market, By Region, From 2021 to 2026 (USD Billion)
  8. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  9. Middle East and Africa Ophthalmic Drugs Market, By Therapeutic Class, From 2021 to 2026 (USD Billion)
  10. Middle East and Africa Anti-inflammatory Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  11. Middle East and Africa Anti-infective Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  12. Middle East and Africa Anti-glaucoma Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  13. Middle East and Africa Anti-allergy Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  14. Middle East and Africa Anti-VEGF Agents Market, By Region, From 2021 to 2026 (USD Billion)
  15. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  16. Middle East and Africa Ophthalmic Drugs Market, By Product Type, From 2021 to 2026 (USD Billion)
  17. Middle East and Africa Prescription Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  18. Middle East and Africa Over-the-Counter Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  19. Middle East and Africa Ophthalmic Drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)
  20. Middle East and Africa Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)
  21. Middle East and Africa Online Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)
  22. Middle East and Africa Independent Pharmacies & Drug Stores Market, By Region, From 2021 to 2026 (USD Billion)
  23. Middle East and Africa Ophthalmic Drugs Market, By Dosage Form, From 2021 to 2026 (USD Billion)
  24. Middle East and Africa Liquid Ophthalmic Drug Forms Market, By Region, From 2021 to 2026 (USD Billion)
  25. Middle East and Africa Solid Ophthalmic Drug Forms Market, By Region, From 2021 to 2026 (USD Billion)
  26. Middle East and Africa Semisolid Ophthalmic Drug Forms Market, By Region, From 2021 to 2026 (USD Billion)
  27. Middle East and Africa Multicompartment Drug Delivery Systems Market, By Region, From 2021 to 2026 (USD Billion)
  28. Middle East and Africa Other Ophthalmic Drug Forms Market, By Region, From 2021 to 2026 (USD Billion)
  29. Middle East and Africa Ophthalmic Drugs Market, By Technology, From 2021 to 2026 (USD Billion)
  30. Middle East and Africa Biologics Market, By Region, From 2021 to 2026 (USD Billion)
  31. Middle East and Africa Cell Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  32. Middle East and Africa Gene Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  33. Middle East and Africa Drug Delivery Market, By Region, From 2021 to 2026 (USD Billion)
  34. Middle East and Africa Small molecule Market, By Region, From 2021 to 2026 (USD Billion)
  35. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  36. Middle East Ophthalmic Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  37. Middle East Ophthalmic Drugs Market, By Therapeutic Class, From 2021 to 2026 (USD Billion)
  38. Middle East Ophthalmic Drugs Market, By Product Type, From 2021 to 2026 (USD Billion)
  39. Middle East Ophthalmic Drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)
  40. Middle East Ophthalmic Drugs Market, By Dosage Form, From 2021 to 2026 (USD Billion)
  41. Middle East Ophthalmic Drugs Market, By Technology, From 2021 to 2026 (USD Billion)
  42. Africa Ophthalmic Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  43. Africa Ophthalmic Drugs Market, By Therapeutic Class, From 2021 to 2026 (USD Billion)
  44. Africa Ophthalmic Drugs Market, By Product Type, From 2021 to 2026 (USD Billion)
  45. Africa Ophthalmic Drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)
  46. Africa Ophthalmic Drugs Market, By Dosage Form, From 2021 to 2026 (USD Billion)
  47. Africa Ophthalmic Drugs Market, By Technology, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample